Moreover, a recent study employing a murine model of colorectal cancer combining oncogenic KRAS expression with conditional null alleles of adenomatous polyposis coli (APC) and TRP53, identified repression of IRF2 as a key mechanism for KRAS-induced immune-suppression in colorectal cancer [23]. The gene discussed is IRF2; the disease is colorectal cancer.